1. Do you provide a lymphoma testing service?
2. Do you participate in an EQA program for lymphoma testing?
3. Approximately how many lymphoma cases are tested? (per month or per year, whichever is easier to determine)?
4. Approximately how many of these samples are B-cell lymphomas? (per month or per year or as a percentage of lymphoma samples above, whichever is easier to determine)?
5. Do you perform DLBCL subtyping?
6. Approximately how many samples are DLBCL positive? (per month or per year, whichever is easier to determine)?
7. Which DLBCL algorithm do you use to classify subtypes?
8. Which IHC antibodies are used for DLBCL subtyping?
9. Which IHC platform/autostainer do you use for DLBCL subtyping?
10. Is Gene Expression Profiling (GEP) used for DLBCL subtyping?
11. Approximately how many DLBCL samples are tested using GEP? (per month or per year, whichever is easier to determine)?
12. If GEP is used to test for DLBCL which platform is used in your lab?
13. What is the laboratory turnaround time for DLBCL subtyping using IHC?
14. What is the laboratory turnaround time for DLBCL subtyping using GEP?
15. Are any additional tests performed to help confirm a diagnosis of DLBCL?
16. If multiple tests are performed to confirm DLBCL, how are the reports issued?
17. Who pays for DLBCL testing?

Download response Lymphoma Subtyping. 051017